<DOC>
	<DOC>NCT00330044</DOC>
	<brief_summary>To determine the safety of Alimta when used with chemoradiation in inoperable non small cell lung cancer</brief_summary>
	<brief_title>Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer</brief_title>
	<detailed_description>To determine the maximal tolerated dose (MTD) and toxicities of Pemetrexed (Alimta) when administered concurrently with carboplatin and thoracic radiation therapy. To determine, qualitatively, the occurrence of local tumor responses identified with this regimen.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Unresectable Stage II, IIIB or IV non small cell lung cancer. Evaluable disease on planning CT scan Zubrod 01 Weight loss equal to or less than 10% 3 months prior to diagnosis FEV1 greater than 1000cc Adequate hematologic, renal and hepatic functions Small cell cancer Stage I non small cell cancer Prior chemotherapy or thoracic or lower neck radiatio therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>